Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

Merck is planning further cuts at its headquarters in New Jersey as part of an ongoing restructuring effort. In a filing with the state Department of Labor & Workforce Development, the pharmaceutical ...

NEW YORK, April 22 (Reuters) - Drugmaker Merck & Co (MRK.N), opens new tab said on Wednesday it will partner with Google Cloud to build up its artificial intelligence capabilities, investing as much ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

Ever bought "stainless" steel and it rusted? Is it fake or is there more to the story? We're busting myths and showing you how to spot real versus fake stainless steel. #engineering #DIY #metals ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. In a Worker Adjustment and Retraining Notification (WARN) Act alert filed ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...

Merck MRK-2.23%decrease; down pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio and ...